Programmable mRNA therapeutics for cancer and autoimmune disease using genetic circuits
Strand Therapeutics is an MIT-spinout developing programmable mRNA therapeutics built on genetic circuits that can sense cellular state and conditionally activate therapeutic payloads. Lead asset STX-001 is in Phase 1 clinical trials for solid tumors via intratumoral delivery, with multiple RECIST responses reported in June 2025. Founded in 2017 by MIT synthetic biologists Jacob Becraft (CEO) and Tasuku Kitada (President & Head of R&D), with Ron Weiss (Becraft's PhD advisor) as cofounder and current advisor. Raised a $153M Series B in August 2025 led by Kinnevik at an estimated $550M post-money valuation (Forbes), up from $359M in November 2024 and just $15.5M at seed in 2019. Total funding to date: $257M across seven rounds including grants from NIH. Big Pharma syndicate includes Regeneron Pharmaceuticals, Amgen Ventures, and Eli Lilly; ICONIQ joined as a new investor in the Series B alongside existing leads FPV Ventures and Playground Global.
Biotech📍 Boston, MAFounded 2017
Current Valuation
$550M
as of 2025-Q3
PRIVATE
QL Price
$550M
0% vs last round
QuantLogix's current estimate for Strand Therapeutics, published 2026-10-07 — in line with the last disclosed round of $550M (2025-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$550M
2025-Q3
weight 0.49
How this price has held up
No round has priced for Strand Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Strand Therapeutics, 2026-10-07 (709e845743594f2a).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Strand Therapeutics going public?
No. Strand Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Strand Therapeutics' valuation in 2026?
Strand Therapeutics is valued at $550M as of 2025-Q3, set by its Series B ($153M, Aug 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Strand Therapeutics filed an S-1?
No public S-1 is on file for Strand Therapeutics.
Who are Strand Therapeutics' investors?
Strand Therapeutics' investors include Kinnevik, ICONIQ Capital, FPV Ventures, Playground Global, ANRI, Redmile Group and 5 more.
How much has Strand Therapeutics raised?
Strand Therapeutics has raised $257.2M in total, most recently a Series B of $153M in Aug 2025.
Is Strand Therapeutics publicly traded — can you buy Strand Therapeutics stock?
No. Strand Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Strand Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Jacob Becraft
Founded
2017
HQ
Boston, MA
Employees
~100
Total Raised
$257.2M
Growth
Pre-revenue clinical-stage biotech
Last Round
Series B — $153M (Aug 2025) · Lead: Kinnevik
IPO Status
private
Fundraising Status
Series B · $153M · 1y 2mo ago
privateTotal raised $257.2M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$153M
Aug 2025
Kinnevik
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
2
2 active · 2 recruiting
Lead phase
Phase 2
most advanced registered study
Focus areas
Advanced Solid Tumor
Latest trial start
2026-06-30
Name-verified against lead sponsor "Strand Therapeutics Inc." on ClinicalTrials.gov as of 2026-10-04. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▼ Hiring downtrend
-25% vs 2026-08
Open roles
3
via greenhouse
Product-build share
67%
engineering, research, product, design
Trajectory
strengthening
heavy product build — 67% of open roles are product-building functions (engineering/research/product) — 2 of 3 open roles are research.
Recent senior hire: 1 senior hire (CFO); open roles trending down.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INKunal BhatiaCFO · 2026-08-26
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Scientist / Senior Scientist, Process Sciences and InnovationSenior Associate Scientist, Cellular Analytical DevelopmentSenior Vice President of Regulatory Sciences
Counted from Strand Therapeutics's live job board as of 2026-09-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Jacob BecraftTasuku KitadaRon Weiss
Investors
Kinnevik · ICONIQ Capital · FPV Ventures · Playground Global · ANRI · Redmile Group · Regeneron Ventures · Amgen Ventures · Eli Lilly · ARCH Venture Partners · Andreessen Horowitz (a16z Bio)
Products
STX-001 (intratumoral mRNA for solid tumors, in clinic)
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q3. Refreshed quarterly.